Docetaxel plus radiation for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding a chemotherapy drug called docetaxel to radiation therapy helps treat head and neck cancer better than radiation alone. It also checks the side effects. This might be an option if your cancer is locally advanced and has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your cancer must be a type called squamous cell carcinoma.
- The cancer must be locally advanced, meaning it has spread to nearby lymph nodes but not to other parts of the body.
- You must be able to have radiation therapy as part of your treatment.
- The cancer must not have spread to distant organs, and you must not have another cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial studies a combination of the chemotherapy drug docetaxel and an investigational drug called SX-682 for people with certain advanced head and neck cancers or prostate cancer. The goal is to see if the combination is safe and effective.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a new way to give radiation therapy for head and neck cancer. By using a special PET scan to guide where higher radiation doses are given, doctors hope to improve treatment while reducing side effects. It is for people whose cancer is not early-stage and who will receive standard radiation therapy.
This trial tests a new way of giving radiation therapy, called adaptive radiation boost, for people with head and neck cancer. The goal is to see if this approach can better target the cancer and possibly improve outcomes.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.